Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes | Journal of Pharmaceutical Policy and Practice | Full Text

Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes | Journal of Pharmaceutical Policy and Practice | Full Text

Journal of Pharmaceutical Policy and Practice

Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes

Glycated hemoglobin (HbA1c) is accepted as the most reliable marker for assessing chronic glycemia. The present study aimed to investigate glycemic control in cardiovascular outcome trials (CVOTs) performed by...

Authors:Rumiko Shimazawa and Masayuki Ikeda

Citation:Journal of Pharmaceutical Policy and Practice 2019 12:30

Content type:Research

Published on: 18 November 2019

• ViewFull Text
 
• ViewPDF